Global Tarsal Tunnel Syndrome Market Trends, Forecast Report 2025-2037
Tarsal Tunnel Syndrome Drugs Market size was over USD 4.3 billion in 2024 and is expected to reach USD 6 billion, witnessing a CAGR of over 7.7% during the forecast period, between 2025-2037. In 2025, the industry size of tarsal tunnel syndrome drugs is estimated at USD 398.17 million.
Annually, the incidence of tarsal tunnel syndrome (TTS) around the world is 2.5 million, as per the estimations from the National Institute of Neurological Disorders and Stroke (NINDS). Adults aged between 40 and 60, living with diabetic neuropathy and occupational strain, are the primary targets of this ailment. Thus, the increasing population of diabetic patients is also propelling the consumer base in the tarsal tunnel syndrome drugs market. The significant demand can also be demonstrated by the worldwide trade of TTS-related drugs and their raw materials, which recently accounted for a yearly 1.4 billion. The popularity of advanced detection and treatment is also gaining traction due to delivering enhanced outcomes.
In this regard, in 2022, an AHRQ study revealed that early intervention with the products from the tarsal tunnel syndrome drugs market could reduce hospitalization by 18.5% while saving over 1.4 billion in healthcare costs over 2 years. Besides this, the rise in payers’ pricing in the sector is also attributable to several other factors, including supply chain disruptions and R&D inflation. Similarly, the 3.2% and 2.4% increases in the producer price index (PPI) and consumer price index (CPI) for pharmaceuticals and pain management medicines, respectively, in 2024, also replicate the need for cost optimization in both production and retailing. In addition, the additional expenses in API procurement due to stringent regulatory criteria also result in an increase in treatment cost.
